<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Neupogen</title>
	<atom:link href="http://www.tapanray.in/tag/neupogen/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Biosimilar Drugs: Why Prescriptions Aren’t Still Enough?</title>
		<link>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilar-drugs-why-prescriptions-arent-still-enough</link>
		<comments>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/#comments</comments>
		<pubDate>Mon, 14 Sep 2015 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[filgrastim]]></category>
		<category><![CDATA[filgrastim-sndz]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Hatch-Waxman]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[M&M]]></category>
		<category><![CDATA[marketsandmarkets]]></category>
		<category><![CDATA[Neupogen]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[QuantiaMD]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[Similar]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Zarxio]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7055</guid>
		<description><![CDATA[On September 3, 2015, in a Press Release, Novartis announced, “Zarxio(TM) (filgrastim-sndz) is now available in the United States. Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA) and the first to launch in the &#8230; <a href="http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
